Vortosiran
Vortosiran (RBD4059) is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran is internalized via ASGPR-mediated endocytosis, subsequently regulating mRNA translation to suppress FXI synthesis. Vortosiran exhibits antithrombotic activity without impairing hemostatic function. Vortosiran can be used in research related to intravascular thrombosis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 3061406-99-0
- 分子式: C463H620F7N154O291P39S6
- 分子量:14532.10
-
保管条件:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
生物活性
製品説明
|
FXI |
ASGPR |
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:female C57BL/6J mice[2]
-
Dosage:1, 3 and 9 mg/kg
-
Administration:s.v.; single dose
-
Result:Prevented arterial and venous thrombosis, but tail bleeding did not prolong.
化学情報
-
CAS 番号 3061406-99-0
-
性状 Solid
-
分子量 14532.10
-
分子式 C463H620F7N154O291P39S6
-
Color White to off-white
-
SMILES
[Vortosiran]
-
別名
RBD4059
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
純度とドキュメンテーション
-
データシート (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2242 KB)
参考文献
[1]. Gabrielsen A, et al. RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran). Blood advances. 2026 Apr 14;10(7):2541-2548. [Content Brief]
[3]. Yuan H, et al. Beyond traditional anticoagulants: exploring the future of thromboembolism treatment with FXI inhibitors. Front Immunol. 2026 Oct 5;17:1925585. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Keywords
- Vortosiran
- 3061406-99-0
- RBD4059
- RBD 4059
- RBD-4059
- Small Interfering RNA (siRNA)
- Factor XI
- Asialoglycoprotein Receptor (ASGPR)
- Asialoglycoprotein Receptor
- Ashwell-Morell Receptor
- coagulation factor XI
- small interfering RNA
- N-acetylgalactosamine
- prothrombin time
- antithrombotic effects
- intravascular thrombosis
- hemostasis
- Inhibitor
- inhibitor
- inhibit